Phaseline

Targets › DRD3

DRD3 (Dopamine receptor D3): drug programs, companies and trials

28 programs from 27 companies in 62 trials: 25 Phase 2, 22 Phase 3, 8 Phase 4, 7 Phase 1; Psychiatry, Neurology, Other; next expected readout Nov 2026.

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P35462)

Open in Phaseline: the race on DRD3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NavamedicLevodopa
Dopamine D3 receptor agonist
DRD3Phase 4PARKINSON DISEASE (Disorder)Mar 2027
Dennis M. McNamara, MD, MSBromocriptine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Peripartum Cardiomyopathy, PostpartumJun 2028
Massachusetts General HospitalPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 4Adrenoleukodystrophy–
Jimma UniversityBromocriptine mesylate
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Dilated CardiomyopathyNov 2026
Gedeon RichterCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3Schizophrenia; Depression, Bipolar; Bipolar I DisorderDec 2026
NeuroDermLevodopa (ND0612)
Dopamine D3 receptor agonist
DRD3Phase 3Parkinson's Disease; Freezing of Gait; Parkinson Disease; Acute Stroke …Feb 2027
AbbVieCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3DepressionMar 2027
LB PharmaceuticalsLB-102
Atypical antipsychotic; dopamine D2/D3 receptor antagonist
DRD2, DRD3Phase 3Schizophrenia; Bipolar I DisorderJun 2027
Daniel LindqvistPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Bipolar Disorder (BD)Dec 2029
Shanghai Mental Health CenterAmisulpride
Atypical antipsychotic; selective dopamine D2 and D3 receptor antagonist
DRD2, DRD3Phase 3Treatment-resistant SchizophreniaDec 2030
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsApomorphine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Idiopathic Parkinson's Disease–
I.R.C.C.S. Fondazione Santa LuciaRotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Alzheimer Disease–
University of California, San DiegoPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Anxiety DisordersNov 2026
BioprojetBP1.4979
Selective dopamine D3 partial agonist
DRD3Phase 2Essential Tremor; Premature (Early) EjaculationDec 2026
University of LiegeApomorphine Hydrochloride
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Disorder of ConsciousnessDec 2026
M.D. Anderson Cancer CenterChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 2DeliriumFeb 2027
M.D. Anderson Cancer CenterHaloperidol
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist
HTR2A, DRD2, DRD3, DRD4Phase 2Delirium; Advanced Malignant Neoplasm; Advanced CancersFeb 2027
Instituto do Cancer do Estado de São PauloAmisulpride
Dopamine D2 and D3 receptor antagonist
DRD2, DRD3Phase 2Post Operative Nausea and Vomiting (PONV)Mar 2027
Boryung PharmaceuticalOlanzapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy …May 2027
Clinical Academic Center (2CA-Braga)Pramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Obsessive-Compulsive DisorderAug 2028
University Hospital, Rouenrotigotine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Kidney DiseasesJul 2030
Stanford UniversityPramipexole
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 2Depression - Major Depressive DisorderAug 2030
Md. Moktadirul Hoque ShuvoTrifluoperazine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Functional Dyspepsia–
Mapi PharmaCariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 1SchizophreniaDec 2026
Serina TherapeuticsSER-252 (PEOZ-apomorphine)
Dopamine receptor agonist (D1-like and D2-like dopamine receptors)
DRD1, DRD2, DRD3, DRD4, DRD5Phase 1PARKINSON DISEASE (Disorder)Jan 2027
University of Pennsylvania[18F]FTP
D3 dopamine receptor radioligand for PET imaging
DRD3Phase 1D3 Dopamine ReceptorJun 2027
Anxo PharmaceuticalAX251 LAI
Dopamine D2/D3 receptor partial agonist
DRD2, DRD3Phase 1SchizophreniaJul 2028
Capital Medical UniversityChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 1Acute Ischemic Stroke–

Conditions

Schizophrenia (7) PARKINSON DISEASE (Disorder) (3) Delirium (3) Bipolar I Disorder (2) Advanced Malignant Solid Neoplasm (2) Multiple Myeloma (2) Parkinson's Disease (2) Essential Tremor (1) Premature (Early) Ejaculation (1) Depression, Bipolar (1) Advanced Malignant Neoplasm (1) Advanced Cancers (1)

Modalities

small molecule (25), protein or peptide (2)

Companies

M.D. Anderson Cancer Center (2) LB Pharmaceuticals (1) Bioprojet (1) Gedeon Richter (1) Serina Therapeutics (1) Boryung Pharmaceutical (1) University of Liege (1) Md. Moktadirul Hoque Shuvo (1) Shanghai Mental Health Center (1) Anxo Pharmaceutical (1) Mapi Pharma (1) AbbVie (1) Daniel Lindqvist (1) Stanford University (1) Navamedic (1) University Hospital, Rouen (1) University of California, San Diego (1) Jimma University (1) NeuroDerm (1) University of Pennsylvania (1)

Related targets

DRD2 (24) DRD4 (17) HTR2A (5) HTR2C (2) DRD1 (1) DRD5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.